SA516371223B1 - لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية - Google Patents

لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية Download PDF

Info

Publication number
SA516371223B1
SA516371223B1 SA516371223A SA516371223A SA516371223B1 SA 516371223 B1 SA516371223 B1 SA 516371223B1 SA 516371223 A SA516371223 A SA 516371223A SA 516371223 A SA516371223 A SA 516371223A SA 516371223 B1 SA516371223 B1 SA 516371223B1
Authority
SA
Saudi Arabia
Prior art keywords
mers
sequence
cov
ser
antigen
Prior art date
Application number
SA516371223A
Other languages
Arabic (ar)
English (en)
Inventor
بي. وينير ديفيد
موثوماني كاروبيا
واي. سارديساي نيرانجان
Original Assignee
انوفيو فارماسيوتيكالز، إنك.
ذي ترستيز أوف ذي يونيفيرستي أوف بنسلفانيا
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by انوفيو فارماسيوتيكالز، إنك., ذي ترستيز أوف ذي يونيفيرستي أوف بنسلفانيا filed Critical انوفيو فارماسيوتيكالز، إنك.
Publication of SA516371223B1 publication Critical patent/SA516371223B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SA516371223A 2013-11-29 2016-05-29 لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية SA516371223B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361910153P 2013-11-29 2013-11-29

Publications (1)

Publication Number Publication Date
SA516371223B1 true SA516371223B1 (ar) 2023-01-31

Family

ID=53199622

Family Applications (1)

Application Number Title Priority Date Filing Date
SA516371223A SA516371223B1 (ar) 2013-11-29 2016-05-29 لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية

Country Status (10)

Country Link
US (5) US10016497B2 (enExample)
EP (1) EP3074051A4 (enExample)
JP (1) JP6412131B2 (enExample)
KR (2) KR20230122181A (enExample)
CN (2) CN105939730B (enExample)
AU (1) AU2014354797C1 (enExample)
CA (1) CA2932055A1 (enExample)
IL (3) IL276210B2 (enExample)
SA (1) SA516371223B1 (enExample)
WO (1) WO2015081155A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9889194B2 (en) 2013-03-01 2018-02-13 New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
KR20230122181A (ko) * 2013-11-29 2023-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
US11103575B2 (en) 2014-02-28 2021-08-31 The New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
EP3045181B1 (en) * 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
US11058779B2 (en) 2015-09-08 2021-07-13 Sirnaomics, Inc. Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
EP3718565B1 (en) 2015-10-22 2022-04-27 ModernaTX, Inc. Respiratory virus vaccines
CN106397549B (zh) * 2016-10-11 2019-08-06 中国疾病预防控制中心病毒病预防控制所 MERS-CoV特异性多肽及其应用
CA3040540A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
KR20180058206A (ko) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2019078600A1 (ko) * 2017-10-19 2019-04-25 (주)에이티젠 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
WO2021158248A1 (en) 2020-02-04 2021-08-12 Oyagen, Inc. Method for treating coronavirus infections
PH12022552249A1 (en) * 2020-02-25 2023-11-13 Inovio Pharmaceuticals Inc Vaccines against coronavirus and methods of use
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
WO2021225344A1 (ko) * 2020-05-08 2021-11-11 한림대학교 산학협력단 코로나 바이러스 억제용 펩타이드 및 그 용도
CN115867313A (zh) * 2020-05-12 2023-03-28 格雷菲克斯公司 作为疫苗抗原的工程化冠状病毒刺突蛋白、其设计和用途
WO2021252604A1 (en) * 2020-06-09 2021-12-16 The Wistar Institute Of Anatomy And Biology Coronavirus disease 2019 (covid-19) combination vaccine
EP4178545A4 (en) * 2020-07-10 2024-08-07 Engimata, Inc IMMUNOGENIC COMPOSITION FORMING A VACCINE AND METHOD OF MANUFACTURE THEREOF
WO2022020604A1 (en) * 2020-07-22 2022-01-27 Greffex, Inc. Multivalent beta-coronavirus vaccines, their design and uses
WO2022025029A1 (ja) * 2020-07-27 2022-02-03 国立大学法人滋賀医科大学 in vitroにおいてコロナウイルス科に属するウイルスを増殖させる方法、コロナウイルス科に属するウイルスに対する中和抗体の産生方法、及びSevere acute respiratory syndrome coronavirus 2の感染モデルの製造方法
EP4196158A1 (en) * 2020-08-14 2023-06-21 Julius-Maximilians-Universität Würzburg Salmonella vaccine for the treatment of coronavirus
WO2022046737A1 (en) * 2020-08-25 2022-03-03 The Wistar Institute Of Anatomy And Biology Intradermal mers-cov vaccine
WO2022051816A1 (en) * 2020-09-10 2022-03-17 The Council Of The Queensland Institute Of Medical Research Methods of determining immune response
WO2022056302A1 (en) * 2020-09-11 2022-03-17 Memgen, Inc. Enhancing immunity using chimeric cd40 ligand and coronavirus vaccine
EP4333887A4 (en) * 2021-05-05 2025-05-21 Inovio Pharmaceuticals, Inc. Vaccines against coronavirus and methods of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
JP2002520101A (ja) 1998-07-13 2002-07-09 ジェネトロニクス、インコーポレーテッド 電気的に補助される化粧用薬剤の局部送達法および装置
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US6520950B1 (en) 1999-05-10 2003-02-18 Genetronics, Inc. Method of electroporation-enhanced delivery of active agents
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
WO2005017133A1 (en) * 2003-08-18 2005-02-24 Amsterdam Institute Of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
CN101098710A (zh) * 2004-06-02 2008-01-02 纽约血液中心 产生高度有效抗体的sars疫苗和方法
EP1766073A4 (en) * 2004-06-04 2007-08-01 Wyeth Corp IMPROVING PROTEIN EXPRESSION
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
JP5852883B2 (ja) * 2008-08-08 2016-02-03 タケダ ワクチン,インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CN103476928B (zh) * 2010-12-09 2017-03-29 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
EP2788478B1 (en) 2011-12-09 2017-08-23 Institut Pasteur Multiplex immuno screening assay
EP2876161B1 (en) * 2012-07-23 2018-12-05 The Institute of Biological Resources Vaccine
SG11201601423SA (en) 2013-09-19 2016-04-28 Novavax Inc Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
KR20230122181A (ko) * 2013-11-29 2023-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Also Published As

Publication number Publication date
US20200222527A1 (en) 2020-07-16
EP3074051A1 (en) 2016-10-05
CA2932055A1 (en) 2015-06-04
US10016497B2 (en) 2018-07-10
US20190022213A1 (en) 2019-01-24
JP6412131B2 (ja) 2018-10-24
IL276210B1 (en) 2023-09-01
AU2014354797A1 (en) 2016-07-07
US10548971B2 (en) 2020-02-04
US20240123056A1 (en) 2024-04-18
WO2015081155A1 (en) 2015-06-04
US20210401972A1 (en) 2021-12-30
JP2016539946A (ja) 2016-12-22
CN112057613A (zh) 2020-12-11
EP3074051A4 (en) 2017-04-12
KR20230122181A (ko) 2023-08-22
AU2014354797B2 (en) 2017-10-26
US11801298B2 (en) 2023-10-31
AU2014354797C1 (en) 2018-02-01
CN105939730B (zh) 2020-09-11
US11135284B2 (en) 2021-10-05
KR20160091350A (ko) 2016-08-02
IL245903B (en) 2020-08-31
IL305392A (en) 2023-10-01
US20170258893A1 (en) 2017-09-14
IL276210B2 (en) 2024-01-01
IL276210A (en) 2020-09-30
IL245903A0 (en) 2016-07-31
CN105939730A (zh) 2016-09-14

Similar Documents

Publication Publication Date Title
SA516371223B1 (ar) لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية
Singh et al. Foot-and-mouth disease virus: immunobiology, advances in vaccines and vaccination strategies addressing vaccine failures—an Indian perspective
Planas et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
UA126848C2 (uk) Філовірусна вакцина на основі рекомбінантного модифікованого вірусу вісповакцини анкара (mva)
TW202146427A (zh) 用於預防冠狀病毒疾病的疫苗組合物
WO2022096899A1 (en) Viral spike proteins and fusion thereof
WO2021262672A1 (en) Sars-cov-2 rbd constructs
Wang et al. Vaccination with a single consensus envelope protein ectodomain sequence administered in a heterologous regimen induces tetravalent immune responses and protection against dengue viruses in mice
Ding et al. Multi-epitope recombinant vaccine induces immunoprotection against mixed infection of Eimeria spp.
Jeong et al. Immune responses of a novel bi-cistronic SARS-CoV-2 DNA vaccine following intradermal immunization with suction delivery
Zeng et al. Exploring the potential of cytomegalovirus-based vectors: a review
Shchelkunov et al. Enhancing the immunogenicity of vaccinia virus
Salleh Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development
Kamel et al. The quest for immunity: exploring human herpesviruses as vaccine vectors
Di et al. The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice
Ren et al. Optimizing encephalomyocarditis virus VP1 protein assembly on pseudorabies virus envelope via US9 protein anchoring
Cui et al. Enhancing immune responses against SARS-CoV-2 variants in aged mice with INDUK: A chimeric DNA vaccine encoding the spike S1-TM subunits
Martínez-Rodrigo et al. Epitope selection for fighting visceral leishmaniosis: not all peptides function the same way
Starodubova et al. Cellular immunogenicity of novel gene immunogens in mice monitored by in vivo imaging
Shen et al. Profiles of B and T cell immune responses elicited by different forms of the hepatitis B virus surface antigen
Pascual-Iglesias et al. An overview of vaccines against SARS-Cov-2 in the COVID-19 pandemic era. Pathogens. 2021; 10: 1030
WO2025083402A1 (en) Coronavirus vaccines
Barbosa et al. A Multi-Epitope Recombinant Vaccine Candidate Against Bovine Alphaherpesvirus 1 and 5 Elicits Robust Immune Responses in Mice and Rabbits
CN119955856A (zh) 一种IBV多表位重组质粒pEGFP-QSN、构建方法及其应用